Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome

Rheumatology (United Kingdom)

Volumn 53, Issue 5, 2014, Pages 960-961

  Tosounidou, Sofia ^a   Macdonald, Hannah ^b   Situnayake, Deva ^c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; COMORBIDITY; HUMANS; MYOSITIS; SCLERODERMA, SYSTEMIC; SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898827756     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket365     Document Type: Letter

References (4)

1. Fisler RE, Liang MG, Fuhlbrigge RC et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
2. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of JDM: a study of composition and treatment. J Pediatr 2008;58:3941-50.
3. Pachman L, Liotta-Davis M, Hong D et al. TNF-a-308A allele in JDM. Arthritis Rheum 2000;43:2368-77.
4. Riley P, McCann LJ, Maillard SM et al. Effectiveness of infliximab in the treatment of refractory JDM with calcinosis. Rheumatology 2008;47:877-80.